Long-term Efficacy and Safety of Exenatide Treatment

Mayo Clinic Proceedings

Volumn 90, Issue 9, 2015, Pages 1304-

  Chirapongsathorn, Sakkarin ^a,b   Anthanont, Pimjai ^a  

^a MAYO CLINIC   (United States)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT DROPOUTS; TREATMENT DURATION; VOMITING; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES; VENOMS;

EID: 84940564556     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.06.004     Document Type: Letter

References (1)

1. C.H. Wysham, L.A. MacConell, D.G. Maggs, M. Zhou, P.S. Griffin, and M.E. Trautmann Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial Mayo Clin Proc 90 3 2015 356 365